Avastin, Genentech/Roche's trade name for bevacizumab, is frequently used to treat various cancers because it blocks the growth of new blood vessels. But all too frequently, some patients develop a resistance to Avastin. Circadian Technologies has found what it says are two biomarkers that indicate which colorectal cancer patients might be resistant to Avastin. VEGF-C and VEGF-D appear to play roles in chemotherapy resistance. More studies are planned. Release